Accelerated approval
According to AstraZeneca, the FDA granted the approval based on an interim analysis of a late-stage trial. Key points: The decision gives patients in the United States a new option while the company gathers longer-term data.
- Ultomiris reduced proteinuria, excess protein in the urine, by 43.4% versus placebo after 34 weeks.
- The trial will continue through 106 weeks to determine whether the drug slows loss of kidney function.
- No new safety concerns were identified in the study.
- Applications are also under review in Japan and other countries.
What is IgA nephropathy?
IgA nephropathy, also known as Berger’s disease, occurs when immunoglobulin A antibodies build up in the kidneys, causing inflammation and gradually damaging the kidneys’ filters. The disease often progresses silently for years and can lead to kidney failure.

















